US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

37.88

+0.63001.69%

Post-market: 37.880.00000.00%19:30 EDT

Volume:52.02K

Turnover:1.97M

Market Cap:342.44M

PE:- -

High:37.97

Open:37.82

Low:37.60

Close:37.25

52wk High:39.80

52wk Low:30.66

Shares:9.04M

Float Shares:9.04M

Volume Ratio:0.80

T/O Rate:0.58%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Press Release: Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

PDS Biotech Reports Second Quarter 2026 Financial Results

Press Release: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

The Pivotal Moment for the Global Risk-Free Rate: A Dovish CPI Surprise Could Trigger a Short Squeeze in Bonds and Boost Risk Assets

Press Release: Erasca Reports Second Quarter 2026 Business Updates and Financial Results

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

Oriole Resources boosts Eastern Cameroon gold prospects, exits Western licences

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Press Release: Immunocore Reports Second Quarter Financial Results and Provides a Business Update

Press Release: Ideaya Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China

Breakthrough BNCT Data: 80% Response Rate in Late-Stage Head and Neck Cancer Patients Treated at Hainan Boron Neutron Hospital

Short Covering May Boost Yen to 150 Per Dollar After Joint Intervention

Overseas Expansion Accelerates: Wall Street Bets China EV Short Squeeze Has Further to Run

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Oriole Resources bolsters board and advisory team as African gold projects advance

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/ORR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":37.88,"timestamp":1790971200000,"preClose":37.25,"halted":0,"volume":52018,"hourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.016912751677852417,"floatShares":9040000,"shares":9040000,"eps":0,"marketStatus":"Market Closed","change":0.63,"latestTime":"10-02 16:00:00 EDT","open":37.82,"high":37.9699,"low":37.6,"amount":1965631.8915940002,"amplitude":0.00993,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":37.25,"sharesOutstanding":12900000,"nav":37.48,"aum":338819200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.798571665918667,"impliedVol":0.202,"impliedVolPercentile":0.7043},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9040000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.798571665918667,"shares":9040000,"dividePrice":0,"high":37.9699,"amplitude":0.00993,"preClose":37.25,"low":37.6,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":37.88,"eps":0,"divideRate":0,"volume":52018,"delay":0,"ttmEps":0,"open":37.82,"prevYearClose":34.16,"prevWeekClose":38.3781,"prevMonthClose":37.77,"prevQuarterClose":37.77,"fiveDayClose":38.3781,"twentyDayClose":39.1754,"sixtyDayClose":36.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659912921","title":"Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659912921","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659912921?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:30","pubTimestamp":1786739400,"startTime":"0","endTime":"0","summary":"$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR (R)$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PR","BK4161","BK4232","BK4139","PXI","CTXR","BK4007","BK4022","CTOR","FXN","ORR","CR","BK4213","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129230","title":"Press Release: Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129230","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129230?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:30","pubTimestamp":1786739400,"startTime":"0","endTime":"0","summary":"$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR(R) launch progressesStrong institutional demand drives growth in total vials ordered and number of institutions ordering","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","LU1169590202.USD","BK4232","R","CTXR","BK4585","BK4022","BK4560","DT","BK4604","03160","LU1169589451.USD","PR","FXN","PXI","BK4555","BK4161","BK4007","LU0348723411.USD","ORR","TM","BK4023","BK4588","CR","BK4139","BK4099","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659415671","title":"Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659415671","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659415671?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708800,"startTime":"0","endTime":"0","summary":"TUDRIQEV in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345284/0/en/replimune-reports-fiscal-first-quarter-2027-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","IBB","NVIB","CR","CNCR","MEDX","SYNB","BK4161","LFSC","LD","CRBU","BK4195","GDOC","BK4230","CAR","GNOM","BK4539","TBXU","BK4588","ORR","BK4022","IBBQ","HYLG","PFS","BK4585","IDNA","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152369","title":"PDS Biotech Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152369?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Aug.  13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344498/37149/en/pds-biotech-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","PFS","BK4092","GDOC","BK4581","IDNA","NVIB","BK4211","ORR","XBI","PDS","MEDX","HYLG","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658749839","title":"Press Release: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658749839","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658749839?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"patients that have been treated with a muzastotug dose of either 10 mg/kg. -- In the combined 10 mg/kg cohorts, muzastotug achieved an overall","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4139","BK4022","COAL","BK4195","ORR","ADAG","BK4232","PFS","HCC","BK4211","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101400396","title":"The Pivotal Moment for the Global Risk-Free Rate: A Dovish CPI Surprise Could Trigger a Short Squeeze in Bonds and Boost Risk Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=1101400396","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101400396?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:53","pubTimestamp":1786528430,"startTime":"0","endTime":"0","summary":"Wall Street strategists are nearly as divided as possible on whether the Federal Reserve will resume rate hikes next month. One point, however, is undisputed: the U.S. CPI inflation report, set for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCHO","IBIE","WTLS","BWX","BBIB","SHY","USIN","PFIX","USHY","ZROZ","IBIK","RYSE","ISHG","USVN","ZBmain","MYCN","VGSH","TIP","IBID","ZTmain","MWNmain","IBIH","UBmain","JPST","BK4535","DBND","IEF","BSV","BBSB","BWZ","MINT","GOLY","SHV","TNmain","IBII","BK4550","LIBD","VGLT","BK4581","IGOV","BOXX","BK4585","LQD","TSYW","UFIV","VCSH","IEI","HYG","UTHY","NGHT","UTWY","EDV","BNDW","ZFmain","AGZD","SGOV","BITC","UBT","TBT","PRMN","AGIH","VGIT","TLH","TMF","BBLB","HYKE","BND","SBND","TLTX","TFJL","IBTK","BK4588","XBIL","MUB","IBTH","ORR","STIP","HMOP","WAMA","MTNmain","AGG","CLSE","TLTW","VCIT","GOVT","CIVG","BK4561","TBJL","LIAJ","FLGV","TLT","BOND","UTRE","BIL","TYO","TLTI","ZNmain","SHRT","BK4504","MUNX","GBIL","TBIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994859","title":"Press Release: Erasca Reports Second Quarter 2026 Business Updates and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994859","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994859?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:01","pubTimestamp":1786478460,"startTime":"0","endTime":"0","summary":"updated preliminary data from the ongoing AURORAS-1 Phase 1 trial in the. U.S., building on the Company's April 2026 announcement with additional. patients and longer follow-up. At the recommended dose for expansion.  of 32 mg once daily , ERAS-0015 demonstrated encouraging. monotherapy activity in second-line or later (2L+) KRAS G12X pancreatic. ductal adenocarcinoma , with a 57% uORR8wk and ongoing treatment. across all responding patients and most enrolled patients.1,2 ERAS-0015. , no treatment-related discontinuations, and a median relative dose. intensity of 100% at both the 24 mg QD and 32 mg QD RDEs.1 The Company","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","IE00B19Z4B17.USD","BK4187","BK4139","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU0566484027.USD","LU1559883803.SGD","DCO","IE0031619046.USD","BK4539","ERAS","ROKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658399001","title":"PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101","url":"https://stock-news.laohu8.com/highlight/detail?id=2658399001","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658399001?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:25","pubTimestamp":1786451100,"startTime":"0","endTime":"0","summary":"PDS0301 Phase 2 clinical data in mCRC and a comprehensive review of capital allocation priorities drive strategic refocus designed to maximize long-term shareholder valuePRINCETON, N.J., Aug.  11, 202","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342690/37149/en/pds-biotech-announces-strategic-refocus-prioritizing-pds0301-in-metastatic-colorectal-cancer-mcrc-and-partnership-strategy-for-pds0101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4581","BK4585","BK4092","ORR","MSS","PDS","BK4113","IDNA","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962215","title":"Oriole Resources boosts Eastern Cameroon gold prospects, exits Western licences","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962215","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962215?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:11","pubTimestamp":1786428684,"startTime":"0","endTime":"0","summary":"An announcement from Oriole Resources PLC ( ($GB:ORR) ) is now available. Oriole Resources has reported highly encouraging early-stage exploration ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oriole-resources-boosts-eastern-cameroon-gold-prospects-exits-western-licences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oriole-resources-boosts-eastern-cameroon-gold-prospects-exits-western-licences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLD","DGZ","IAU","ORR","SGDM","DZZ","GDXY","CEF","KGLD","1OZmain","GBUG","AAAU","BAR","PICK","PPI","SHNY","DULL","GDXD","OUNZ","JDST","FGDL","XME","BGLD","JNUG","BEGS","BTGD","GLDM","GLTR","EML","IGLD","UYM","DUST","IAUM","WRN","GDXU","UGL","GDXJ","GLDY","SGOL","DBC","GDX","GLL","GOLY","PHYS","YGLD","DGP","RING","USG","IAUI","GOAU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661174","title":"Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661174","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661174?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"Selectedzovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory fee","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340712/0/en/Relay-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","ORR","BK4139","MEDX","RLAY","WT","GDOC","BK4563","IE00BHPRN162.USD","IDNA","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763104","title":"Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763104","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763104?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015800,"startTime":"0","endTime":"0","summary":"The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340156/0/en/Compass-Therapeutics-Reports-2026-Second-Quarter-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTFX","GBTC","BFAP","CBOJ","BTRN","ORR","BFJL","XBTY","YBTC","CBOY","BAGY","BITY","BTCW","BTCL","BPI","MNRS","BTC","BTCO","BTCZ","HODL","SBIT","BETH","DEFI","CBXO","DFII","CBTO","BITO","BRRR","BTCC","CBTY","MAXI","BTCI","CBXJ","CMPX","EZBC","BCCC","CBTJ","BTF","BITU","BITB","ARKB","QBF","CBTA","FBTC","BITX","CBXY","IBIT","CBOO","CBOA","CBXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680141","title":"Press Release: Immunocore Reports Second Quarter Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680141","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680141?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"Immunocore reports second quarter financial results and provides a business updateKIMMTRAK(R) (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-yearEnrollment in P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4139","BK4505","BK4207","BK4007","BK4022","BK4147","CM","ORR","PROC","IMCR","R","ATOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656349575","title":"Press Release: Ideaya Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656349575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656349575?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:00","pubTimestamp":1785837600,"startTime":"0","endTime":"0","summary":"-- Registrational OptimUM-02 trial of the darovasertib combination in. metastatic uveal melanoma  met its primary endpoint; new drug. application  filing is underway under the real-time oncology review. -- Updated data from Phase 2 OptimUM-01 trial (HLA*A2-positive mUM patient. subset) and Phase 2 OptimUM-09 trial  to be. -- Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1. ADC) in small-cell lung cancer  and neuroendocrine carcinomas . -- Announced clinical collaboration with Roche to evaluate IDE892  in. cancer; targeting to initiate a Phase 1 combination trial in H2 2026. -- IDEAYA to host an R&D Day in Q4 focused on MTAP/CDKN2A, KRAS, and. -- $1.24 billion of cash, cash equivalents, and marketable securities as of. June 30, 2026; cash runway guidance into 2030 is unchanged based on. a late-breaking oral presentation at the 2026 American Society of. Clinical Oncology  meeting in Chicago, Illinois.  Data were from a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PARG","BK4023","IDYA","ORR","BK4195","BK4139","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656816825","title":"InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2656816825","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656816825?lang=en_us&edition=fundamental","pubTime":"2026-08-04 10:48","pubTimestamp":1785811680,"startTime":"0","endTime":"0","summary":"BEIJING, Aug.  03, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3337999/0/en/InnoCare-Announces-Orelabrutinib-in-Combination-with-Mesutoclax-Granted-Breakthrough-Therapy-Designation-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIL","ORR","XME","GDXJ","SGDM","LU1223083913.SGD","BK4017","CDE","LU1223082519.USD","LU1223082196.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112255437","title":"Breakthrough BNCT Data: 80% Response Rate in Late-Stage Head and Neck Cancer Patients Treated at Hainan Boron Neutron Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=1112255437","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112255437?lang=en_us&edition=fundamental","pubTime":"2026-08-03 13:16","pubTimestamp":1785734180,"startTime":"0","endTime":"0","summary":"CH BIOTECH SER (08037) subsidiary, Pengbo (Hainan) Boron Neutron Hospital, has released its first batch of real-world clinical data from the initial ten head and neck cancer patients treated with...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037","BK1511","BK1219","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119935982","title":"Short Covering May Boost Yen to 150 Per Dollar After Joint Intervention","url":"https://stock-news.laohu8.com/highlight/detail?id=1119935982","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119935982?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:00","pubTimestamp":1785726027,"startTime":"0","endTime":"0","summary":" Analysts suggest that the large accumulation of speculative short positions in the yen prior to Japan's latest market intervention could amplify the currency's rebound if traders begin to unwind...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WTLS","USDU","HEWJ","SHRT","PRMN","ORR","CLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143143703","title":"Overseas Expansion Accelerates: Wall Street Bets China EV Short Squeeze Has Further to Run","url":"https://stock-news.laohu8.com/highlight/detail?id=1143143703","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143143703?lang=en_us&edition=fundamental","pubTime":"2026-08-03 10:48","pubTimestamp":1785725329,"startTime":"0","endTime":"0","summary":"Stronger-than-expected China new energy vehicle sales in July, alongside rising exports and easing inventory pressures, have prompted Wall Street to upgrade its outlook for automotive stock trading...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRMN","ORR","SHRT","FAZ","KBA","WTLS","CLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872437","title":"Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872437?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:35","pubTimestamp":1785411300,"startTime":"0","endTime":"0","summary":"Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-00","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335951/0/en/Crescent-Biopharma-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4211","XBI","BK4581","BK4585","BK4195","BK4588","ORR","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655185158","title":"Oriole Resources bolsters board and advisory team as African gold projects advance","url":"https://stock-news.laohu8.com/highlight/detail?id=2655185158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655185158?lang=en_us&edition=fundamental","pubTime":"2026-07-29 14:09","pubTimestamp":1785305368,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Oriole Resources PLC ( ($GB:ORR) ). Oriole Resources has strengthened its board and advisory team as it advance...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oriole-resources-bolsters-board-and-advisory-team-as-african-gold-projects-advance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oriole-resources-bolsters-board-and-advisory-team-as-african-gold-projects-advance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAAU","PPI","IAUM","BK4207","DUST","GLDM","OUNZ","GDXD","GLTR","BAR","IGLD","RING","BTGD","UGL","YGLD","DULL","SGDM","GDXU","GOAU","FGDL","USG","DGP","GLDY","SHNY","BK4504","GDXY","DZZ","KGLD","PICK","DBC","BEGS","XME","SGOL","GBUG","ORR","GLD","IAUI","1OZmain","BGLD","GDX","GOLY","GDXJ","JDST","IAU","GLL","UYM","PHYS","DGZ","CEF","JNUG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":118,"code":"91000000","status":"200"}]}}